Adding Chemotherapy to Radiotherapy Not Associated with Improved OS for Patients with Intermediate-Risk Cervical Cancer By Ogkologos - April 7, 2025 548 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a cohort study conducted at Commission on Cancer accredited centres across the US Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed December 9, 2021 Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... March 21, 2025 Load more HOT NEWS Making Cancer Care More Equitable: A Cancer Survivor’s Story FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... Personalised blood test could help predict which lung cancers might return
